Recently, ATR inhibitors showed to sensitize tumor cells to topoisomerase inhibitors already used in clinical trials, thus suggesting the possibility of a combined strategy to enhance cancer treatment efficacy [45]. The gene discussed is ATR; the disease is neoplasm.